
The national board of Science for Life Laboratory

Minutes from board meeting nr 23 2017-02-08 (Stockholm)

Present members: Carl-Henrik Heldin (chair), Sophia Hober (KTH), Anders Karlhede (SU), Margareta Olsson Birgersson (industry representative), Stellan Sandler (UU), Marianne Sommarin (UmU) (left after point 11).

Absent members: Staffan Edén (GU), Henrik Grönberg (KI), Gunilla Westergren-Thorsson (LU)

Other participants: Olli Kallioniemi (Director), Lena Claesson-Welsh (Co-Director) (left after point 5), Annika Jensen (Infrastructure Director), Fredrik Sterky (secretary), Eva Molin, Per Arvidsson (point 7) and Kristian Sandberg (point 7), Sverker Lundin (point 14).

Appendices:

- A. Distribution of funding to DDD in Stockholm/Uppsala.
 - B. Platform executives 2017
-

1. Introduction

Carl-Henrik Heldin opened the meeting.

Decisions:

- The board approved the minutes from meeting nr 21 and 22.
- The board appointed Sophia Hober to adjust the minutes in addition to the chair.

2. Update from the Director

Olli Kallioniemi presented an update about SciLifeLab and current work within the management group. A few extra agenda items were introduced (see below).

3. SciLifeLab annual report

Olli Kallioniemi presented the draft annual report. The KTH board will take the formal decision about approval of the report, after approval by the SciLifeLab board. There were a few comments on minor wordings in the text.

- The board approved the annual report for SciLifeLab 2016 and asked Fredrik Sterky to send it for approval by the KTH board.

4. Budget for facilities

Annika Jensen presented the budget decided in November and the phase out model applied for some facilities. The model involves a complete stop for funding of resource building activities, but this proved to have dramatic

SciLifeLab

effects for two facilities that also have their infrastructure funding phase down. After negotiations, the phase out model for infrastructures was suggested to be applied also for resource building in these facilities during 2017, in order to help them deal with the consequences on personnel.

- The SciLifeLab board decides to approve additional funding of 304 kSEK to Tissue profiling and 800 kSEK to Fluorescent tissue profiling for 2017 in order to close the resource building activities in a controlled way. Resource building efforts in other SciLifeLab facilities will be discontinued in 2017 without a phase-down funding.

SciLifeLab board decided in Dec 2016 to fund High Throughput Genome Engineering (HTGE), previously KHTC (Karolinska High Throughput Center at MBB/KI), with Jussi Taipale as Facility Director. HTGE received a two-year funding of 2.8 MSEK/yr with a potential for extension. KHTC had already started the transformation to HTGE during 2016. To cover the costs of phasing down old operations and phase over KHTC to the HTGE, an additional one-year support of 0.8 MSEK was provided in Dec 2016. Due to extra costs of this transition it is now suggested that the board approves an extra 0.5 MSEK of funding from the national SciLifeLab funding to this purpose*. As Jussi Taipale later resigned as a Facility Director for HTGE, this transition has become more difficult and all efforts should be made to ensure that the new HTGE national service would be set up smoothly.

- The SciLifeLab board decided to add 500 kSEK to KHTC funding during 2017 to close its operations as a national facility during 2017. However, this funding as well as the previously approved 800 kSEK (total 1,3 MSEK) are allocated under the condition that the transition to the new HTGE unit will be successful and will go smoothly and that all parties give their support to this transition.

*Olli Kallioniemi left the room during the discussion and decision on this topic due to a risk of conflict of interest

5. Funding decisions by the Director

Olli Kallioniemi described today's budget process where the board decides upon each budget request. The budget allows some degree of freedom within each budget item, but often there is a need for strategic decisions or modifications of the budget that go beyond the items decided and which need to be resolved quickly. For example, there may be a need for compensation to facilities for unexpected costs, equipment upgrades, management and reporting functions, education, outreach and research activities, or networking and collaborations with the society. *

- The SciLifeLab board decided to give the Director of SciLifeLab authority to take ad hoc decisions about SciLifeLab funding, in addition of the approved annual budget, up to a maximum of 5 MSEK per year. However, important decisions must be taken by board. Each decision should be discussed with the

MG, documented, registered and presented to the board at the following meeting and to the KTH as a summary at the end of the budget year.

*Olli Kallioniemi left the room during the discussion and decisions on this topic due to a risk of conflict of interest

6. Program for the IAB meeting

Olli Kallioniemi presented the plans for the meeting with the International Advisory Board (IAB) in March 2017. Among the items for discussions is a review of past two years, and future long-term plans, an updated mission and vision statement, a new organization and management structure of SciLifeLab, a suggestion to implement research programs, life cycle of facilities and the possibility for launching a call for national pilot facilities, improved coordination of SciLifeLab fellows program.

- The board approved the outline of the SAB visit.

7. DDD update

Per Arvidsson presented an update of the work and organization within the platform Drug Discovery and Development (DDD).

The MG will continue to work with DDD on urgent IP and legal challenges facing SciLifeLab as a whole, but DDD platform in particular. A suggestion will be developed for rectors after discussion with IAB.

8. DDD funding distribution

Annika Jensen presented the funding distribution for DDD. The total funding 2017 to DDD in Stockholm and Uppsala was decided in November 2016, and that DDD has now suggested an internal distribution of DDD funding to its facilities.

- The board approved the distribution of funding to DDD facilities in Stockholm and Uppsala for 2017 (appendix A).

9. Platform governance and policies

Annika Jensen described the work with directives for platform governance and policies. The DDD platform has special requests from its board to have the mandate to decide on funding distribution and prioritizations. The DDD board has requested an extension of the mandate as it was described before.

- The board decided to approve the prolongation of the mandate of the DDD board on an interim basis until a new long-term solution has been found. Carl-Henrik Heldin will negotiate with the chair of the DDD board.

10. Platform Directors 2017

Annika Jensen presented the list of suggested Platform Directors and vice Platform Directors that have been suggested by the Facility Director.

- The board decided to approve the suggested Platform Directors and vice Platform Directors according to the list in Appendix B.

- The board asked Olli Kallioniemi to develop future routines to achieve a better gender balance among the platform executives.

11. Executing new organization

Olli Kallioniemi informed the board about the recent discussions of how to implement the new organization and the preliminary roles of the Scientific Directors and the Integration Directors. The exact responsibilities will be documented in the steering documents that are being prepared.

12. National fellows program

Olli Kallioniemi described recent appointments under the National Fellows program. Three positions are in place at non-host universities. However, the situation has changed since the program was initiated. The present positions were hard to get in place and the new Wallenberg Center for Molecular Medicine (WCMM) program allows for new opportunities to build a national network of researchers around SciLifeLab.

- The Board decided not to continue the recruitment of more National Fellows, but to proceed according to the initial plan with the ones already decided.

13. Update on co-director recruitment

Carl-Henrik Heldin informed the board about the status of the recruitment of the co-Director.

14. National genomics projects

Olli Kallioniemi presented the status of the planned new announcement for national genomics projects. There are still some details to be defined, but a draft text for a call for proposals was presented. Lessons have been learned from previous rounds of the national projects to improve the processes for project calls, specifications for proposals, selection and execution. Approximately 30 MSEK is available for this last round of projects, which are suggested to be organized in two programs, i.e. Swedish genomes and biodiversity.

- The Board decided to give Olli Kallioniemi the mandate to execute a third announcement of national projects, including assignment of chairs for each program, the announcement text and the evaluation panel for both programs. The proposed projects will be presented for a final board funding decision in the fall of 2017.

15. Procedure to launch NAB

Olli Kallioniemi described the status of the plans to establish a national advisory board (NAB) that would be reporting to the management group and give advice on best practice for implementation of infrastructure

initiatives and other SciLifeLab operations that the International Advisory board cannot advice on.

16. Other issues

Anders Karlhede presented a request from the Museum of National history (NRM) for SciLifeLab to be partner in an application. SciLifeLab cannot be an official legal partner in a VR application, and therefore this should involve the necessary facility and its host University. NRM will be invited to the management group on February 9 to present the suggestion.

Olli Kallioniemi presented a request from NGI and NBIS for commitments regarding co-funding of purchases of new instruments.

- The board decided to ask Olli Kallioniemi to discuss the issue of renewal of instruments with the management group and draft a letter to the platform executives, the host universities and VR. Any necessary decision can be brought to the board for a per capsulam decision.


Upcoming meetings:

May 15, 2017 (Uppsala) (exact time to be decided)

August 29, 2017 at 10.00-15.00 in Stockholm (Alfa 5)

November 9, 2017 at 10.00-15.00 in Stockholm (Alfa 5)

Fredrik Sterky, secretary



Minutes approved by:

Carl-Henrik Heldin



Sophia Hober



Appendix A: Distribution of funding to DDD in Stockholm/Uppsala

The SciLifeLab board decides to approve the distribution of funding to the facilities within Drug Discovery and Development (DDD) according to the suggestion from the DDD steering group. This only applies to facilities in Stockholm and Uppsala, and does not include earlier decisions about DDD funding to facilities outside the host universities. Moreover, it does not include DDD:s part of costs for Operations Office activities.

DDD Sthlm/Uppsala

Facility	KTH	KI	SU	UU	Total
ADME				4 029 525	4 029 525
Biochemical and Cellular Assays			5 008 189		5 008 189
Biophysical Screening and Characterization				2 043 878	2 043 878
Human Antibody Therapeutics	5 086 836				5 086 836
In Vitro and Systems Pharmacology				2 916 946	2 916 946
Medicinal Chemistry-Hit2Lead			6 345 939		6 345 939
Medicinal Chemistry-Lead Identification				3 674 615	3 674 615
Protein Expression and Characterization	4 360 998				4 360 998
Swetox		1 000 000			1 000 000
Target Product Profiling&Drug Safety Assessment	1 515 789	2 328 573		2 823 786	6 668 148
Compound Center		999 926			999 926
	10 963 623	4 328 499	11 354 128	15 488 751	42 135 000

Appendix B: Platform executives 2017

The Facility Directors have after internal discussions suggested Platform Directors and vice Platform Directors according to below. The list was approved by the board for 2017.

Platform	Position	Name	University
Bioinformatics	Platform Director	Bengt Persson	UU
Bioinformatics	vice platform director	Erik Lindahl	SU
Cellular & Molecular Imaging / Molecular Structure	Platform Director	Hjalmar Brismar	KTH
Cellular & Molecular Imaging / Molecular Structure	vice platform director	Göran Karlsson	GU
Chemical Biology & Genome Engineering	Platform Director	Anna-Lena Gustavsson	KI
Chemical Biology & Genome Engineering	vice platform director	Johan Ledin	UU
Diagnostics Development	Platform Director	Richard Rosenquist Brandell	UU
Diagnostics Development	vice platform director	Lars Engstrand	KI
Drug Discovery and Development	Platform Director	Per Arvidsson	KI
Drug Discovery and Development	vice platform director	Kristian Sandberg	UU
Genomics	Platform Director	Joakim Lundeberg	KTH
Genomics	vice platform director	Ann-Christine Syvänen	UU
Proteomics/Metabolomics	Platform Director	Peter Nilsson	KTH
Proteomics/Metabolomics	vice platform director	Janne Lehtiö	KI
Single-cell Biology	Platform Director	Sten Linnarsson	KI
Single-cell Biology	vice platform director	Stefan Bertilsson	UU